Association of estrogen receptor alpha and beta3-adrenergic receptor polymorphisms with endometrial cancer

• Published in: Obstetrics and gynecology (New York. 1953) Vol. 102; no. 3; pp. 506 - 511
• Main Authors: Iwamoto, Ichiro, Fujino, Toshinori, Douchi, Tsutomu, Nagata, Yukihiro
• Format: Journal Article
• Language: English
• Published: United States 01.09.2003
• Subjects: Age Distribution; Case-Control Studies; Cohort Studies; Confidence Intervals; Endometrial Neoplasms - epidemiology; Endometrial Neoplasms - genetics; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genotype; Humans; Incidence; Japan - epidemiology; Menopause; Middle Aged; Odds Ratio; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Probability; Receptors, Adrenergic, beta-3 - genetics; Receptors, Estrogen - genetics; Reference Values; Risk Assessment; Japan
• ISSN: 0029-7844

To investigate the association of estrogen receptor alpha and beta3-adrenergic receptor polymorphisms with endometrial cancer risk in Kagoshima, Japan. Ninety-two patients with endometrial cancer and 65 healthy women were enrolled in this study. Blood samples were collected, and deoxyribonucleic acid (DNA) was extracted. Estrogen receptor alpha and beta3-adrenergic receptor gene variants were analyzed by restriction fragment length polymorphisms using the restriction enzymes, Pvu II, Xba I for estrogen receptor alpha, and Mva I for beta3-adrenergic receptor. Multivariable logistic regression analysis was performed, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. The Pvu II PP genotype was associated with a decreased risk of endometrial cancer (multivariable OR 0.23; 95% CI 0.07, 0.82) compared with the pp genotype. The Xba I XX genotype was associated with a decreased risk for endometrial cancer (multivariable OR 0.26; 95% CI 0.09, 0.79) compared with the xx genotype. The Mva I variants were not associated with endometrial cancer risk (multivariable OR 0.55; 95% CI 0.20, 1.51). Estrogen receptor alpha polymorphisms, but not beta3-adrenergic receptor gene, may be associated with a risk of endometrial cancer.